.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ03_Lixisenatide.Lixisenatide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ03_Lixisenatide.Lixisenatide| name: | Lixisenatide | |
| ATC code: | A10BJ03 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 100 | L |
| clearance: | 35 | L/h |
| other parameters in model implementation | ||
Lixisenatide is a once-daily injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) used to improve glycemic control in adults with type 2 diabetes mellitus. It enhances glucose-dependent insulin secretion and suppresses glucagon secretion. Lixisenatide is currently approved and marketed for clinical use in several countries.
Pharmacokinetic parameters from healthy adult subjects, both sexes, under fasting conditions after subcutaneous administration.
Doggrell, SA (2018). Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?. Expert opinion on drug metabolism & toxicology 14(3) 371–377. DOI:10.1080/17425255.2018.1441286 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29439603